Acerus Approved to Trade on the OTCQB Venture Market under the Symbol ASPCF
TORONTO--(BUSINESS WIRE)--May 8, 2019--Acerus Pharmaceuticals Corporation (“Acerus” or “the Company”) (TSX:ASP; OTCQB:ASPCF) announced today its shares have been approved to be quoted on the OTCQB Venture Market and will trade under the symbol “ASPCF” effective immediately. Real-time information, quotes and the trading statistics can be found at www.otcmarkets.com. This is the latest development in the Company’s strategy to provide improved channels for market participation.
“Listing on the OTCQB Venture is part of a long-term strategy to introduce the Company to a broader audience,” said Ed Gudaitis, President & CEO of Acerus. “We believe trading on the OTCQB will help us enhance liquidity by providing our current and future American investors with a trading platform.”
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or the securities laws of any state and may not be offered or sold within the United States or to or for the benefit or account of U.S. persons, absent such registration or an applicable exemption from such registration requirements.
About Acerus Pharmaceuticals Corporation
Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve patient experience, with a primary focus in the field of men’s and women’s health. The Company commercializes its products via its own salesforce in Canada, and through a global network of licensed distributors in the U.S. and other territories.
Information in this press release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 4, 2019 that is available at www.sedar.com . Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190508005121/en/
CONTACT: Robert Motz
Chief Financial Officer
Acerus Pharmaceuticals Corporation
KEYWORD: NORTH AMERICA CANADA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL PROFESSIONAL SERVICES FINANCE
SOURCE: Acerus Pharmaceuticals Corporation
Copyright Business Wire 2019.
PUB: 05/08/2019 07:00 AM/DISC: 05/08/2019 07:01 AM